APLS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $51,199,751.25

Apellis Pharmaceuticals Insider Trading History Chart

Apellis Pharmaceuticals Share Price & Price History

^$47.53

▲ +0.02 (0.04%)

As of 04/19/2024 01:00 AM ET

Days: 30 | 90 | 365

Tiny Biotech Stock Wins $75 Billion Patent

From Behind the Markets | Ad

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

Apellis Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/8/2024	Pascal Deschatelets	Insider	Sell	69,107	$54.17	$3,743,526.19	1,115,983
4/1/2024	Timothy Eugene Sullivan	CFO	Sell	4,000	$58.66	$234,640.00	93,338
3/19/2024	A. Sinclair Dunlop	Director	Sell	18,681	$57.18	$1,068,179.58	173,998
3/18/2024	Mark Jeffrey DeLong	Insider	Sell	9,913	$56.90	$564,049.70	54,693
3/15/2024	James George Chopas	CAO	Sell	184	$56.46	$10,388.64	38,883
3/13/2024	Nur Nicholson	Insider	Sell	11,220	$57.56	$645,823.20	56,287
3/1/2024	Cedric Francois	CEO	Sell	250,000	$64.11	$16,027,500.00	313,662
3/1/2024	Timothy Eugene Sullivan	CFO	Sell	6,000	$63.22	$379,320.00	93,338
2/12/2024	Adam J. Townsend	Insider	Sell	1,148	$67.77	$77,799.96	92,453
2/12/2024	Cedric Francois	CEO	Sell	3,962	$67.77	$268,504.74	313,662
2/12/2024	David O. Watson	General Counsel	Sell	781	$67.77	$52,928.37	103,390
2/12/2024	Timothy Eugene Sullivan	CFO	Sell	1,431	$67.77	$96,978.87	93,338
1/29/2024	Cedric Francois	CEO	Sell	2,843	$64.14	$182,350.02	317,624
1/29/2024	David O. Watson	General Counsel	Sell	906	$64.14	$58,110.84	104,171
1/29/2024	Nur Nicholson	Insider	Sell	835	$64.14	$53,556.90	67,507
1/22/2024	Adam J. Townsend	Insider	Sell	3,413	$65.00	$221,845.00	94,507
1/22/2024	Cedric Francois	CEO	Sell	13,431	$65.00	$873,015.00	320,467
1/22/2024	David O. Watson	General Counsel	Sell	4,184	$65.00	$271,960.00	105,077
1/22/2024	James George Chopas	CAO	Sell	1,061	$65.00	$68,965.00	39,067
1/22/2024	Timothy Eugene Sullivan	CFO	Sell	3,551	$65.00	$230,815.00	95,675
1/16/2024	Cedric Francois	CEO	Sell	7,851	$66.81	$524,525.31	333,898
1/16/2024	David O. Watson	General Counsel	Sell	4,240	$66.81	$283,274.40	109,261
1/16/2024	James George Chopas	CAO	Sell	864	$66.81	$57,723.84	40,128
1/16/2024	Jeffrey Eisele	Insider	Sell	438	$66.81	$29,262.78	72,650
1/16/2024	Timothy Eugene Sullivan	CFO	Sell	2,235	$66.81	$149,320.35	99,226
1/4/2024	Caroline Baumal	Insider	Sell	2,751	$60.05	$165,197.55	32,931
12/26/2023	Jeffrey Eisele	Insider	Sell	68	$57.86	$3,934.48	53,815
12/19/2023	David O. Watson	General Counsel	Sell	3,905	$57.23	$223,483.15	89,753
12/1/2023	Lukas Scheibler	Insider	Sell	10,000	$60.00	$600,000.00	68,299
11/21/2023	Cedric Francois	CEO	Sell	5,000	$48.80	$244,000.00	269,655
11/17/2023	Alec Machiels	Director	Sell	1,250	$47.74	$59,675.00	367,420
11/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$47.27	$567,240.00	1,071,807
10/23/2023	James George Chopas	CAO	Sell	132	$46.04	$6,077.28	32,680
10/23/2023	Mark Jeffrey DeLong	Insider	Sell	131	$46.04	$6,031.24	51,622
10/17/2023	Alec Machiels	Director	Sell	1,250	$48.50	$60,625.00	367,420
10/9/2023	Pascal Deschatelets	Insider	Sell	12,000	$40.38	$484,560.00	1,066,313
9/18/2023	Alec Machiels	Director	Sell	1,250	$45.00	$56,250.00	367,420
9/18/2023	Nur Nicholson	Insider	Sell	20,350	$44.27	$900,894.50	53,284
9/15/2023	Alec Machiels	Director	Sell	1,250	$45.34	$56,675.00	367,420
9/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$42.87	$514,440.00	1,059,813
9/1/2023	Cedric Francois	CEO	Sell	150,000	$41.75	$6,262,500.00	424,655
8/31/2023	James George Chopas	CAO	Sell	551	$41.23	$22,717.73	30,312
8/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$23.66	$283,920.00	1,053,313
7/17/2023	Alec Machiels	Director	Sell	1,250	$64.79	$80,987.50	267,641
7/10/2023	Pascal Deschatelets	Insider	Sell	12,000	$84.55	$1,014,600.00	1,046,813
7/3/2023	David O. Watson	General Counsel	Sell	8,510	$89.98	$765,729.80	85,753
7/3/2023	Timothy Eugene Sullivan	CFO	Sell	6,779	$89.97	$609,906.63	77,713
6/20/2023	Alec Machiels	Director	Sell	1,250	$88.41	$110,512.50	267,641
6/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$91.35	$1,096,200.00	1,040,313
6/5/2023	Timothy Eugene Sullivan	CFO	Sell	69,779	$88.80	$6,196,375.20	77,713
6/1/2023	Karen Lewis	Insider	Sell	5,000	$86.00	$430,000.00	41,504
5/17/2023	Alec Machiels	Director	Sell	1,250	$88.66	$110,825.00	267,641
5/16/2023	Cedric Francois	CEO	Sell	30,000	$85.66	$2,569,800.00	274,655
5/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$92.39	$1,108,680.00	1,033,813
5/3/2023	Adam J. Townsend	Insider	Sell	5,000	$82.71	$413,550.00	75,995
4/18/2023	Cedric Francois	CEO	Sell	30,000	$82.02	$2,460,600.00	637,601
4/17/2023	Alec Machiels	Director	Sell	1,250	$81.05	$101,312.50	267,641
4/10/2023	Pascal Deschatelets	Insider	Sell	12,000	$78.21	$938,520.00	1,027,313
4/3/2023	A. Sinclair Dunlop	Director	Sell	500	$74.05	$37,025.00	131,297
4/3/2023	Karen Lewis	Insider	Sell	5,000	$75.00	$375,000.00	41,430
3/21/2023	Cedric Francois	CEO	Sell	30,000	$62.74	$1,882,200.00	1,144,591
3/17/2023	Alec Machiels	Director	Sell	1,250	$64.03	$80,037.50	267,641
3/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$63.79	$765,480.00	1,020,813
2/23/2023	Jeffrey Eisele	Insider	Sell	1,646	$68.76	$113,178.96	53,883
2/8/2023	Pascal Deschatelets	Insider	Sell	12,000	$54.45	$653,400.00	1,006,756
2/3/2023	Adam J. Townsend	Insider	Sell	5,000	$55.85	$279,250.00	67,932
1/30/2023	Jeffrey Eisele	Insider	Sell	883	$52.76	$46,587.08	46,468
1/23/2023	Karen Lewis	Insider	Sell	2,955	$51.58	$152,418.90	37,709
1/17/2023	Alec Machiels	Director	Sell	1,250	$52.42	$65,525.00	267,641
1/9/2023	Pascal Deschatelets	Insider	Sell	12,000	$46.08	$552,960.00	983,780
1/5/2023	Federico Grossi	Insider	Sell	2,500	$48.79	$121,975.00	94,884
1/3/2023	A. Sinclair Dunlop	Director	Sell	500	$50.70	$25,350.00	132,797
1/3/2023	Adam J. Townsend	Insider	Sell	5,000	$50.70	$253,500.00	42,907
12/19/2022	Cedric Francois	CEO	Sell	28,200	$52.06	$1,468,092.00	965,128
12/15/2022	Alec Machiels	Director	Sell	1,250	$52.35	$65,437.50	263,774
12/8/2022	Pascal Deschatelets	Insider	Sell	12,000	$47.50	$570,000.00	970,280
12/5/2022	Adam J. Townsend	Insider	Sell	5,000	$50.38	$251,900.00	42,907
12/1/2022	A. Sinclair Dunlop	Director	Sell	500	$49.93	$24,965.00	129,430
12/1/2022	Federico Grossi	Insider	Sell	2,500	$49.93	$124,825.00	97,384
11/8/2022	Pascal Deschatelets	Insider	Sell	12,000	$46.47	$557,640.00	963,780
11/3/2022	Adam J. Townsend	Insider	Sell	5,000	$58.54	$292,700.00	42,907
10/14/2022	Alec Machiels	Director	Sell	1,250	$59.31	$74,137.50	263,774
10/10/2022	Pascal Deschatelets	Insider	Sell	12,000	$57.50	$690,000.00	957,280
10/3/2022	Federico Grossi	Insider	Sell	2,500	$66.69	$166,725.00	102,384
9/15/2022	Alec Machiels	Director	Sell	1,250	$66.00	$82,500.00	263,774
9/8/2022	Pascal Deschatelets	Insider	Sell	12,000	$63.98	$767,760.00	950,780
8/17/2022	Mark Jeffrey DeLong	SVP	Sell	5,000	$69.50	$347,500.00	29,250
8/15/2022	Adam J. Townsend	Insider	Sell	12,500	$69.00	$862,500.00	42,907
8/15/2022	Alec Machiels	Director	Sell	1,250	$67.21	$84,012.50	263,774
8/11/2022	A. Sinclair Dunlop	Director	Sell	30,000	$65.63	$1,968,900.00	255,679
8/11/2022	Adam J. Townsend	Insider	Sell	12,500	$67.00	$837,500.00	42,907
8/11/2022	Mark Jeffrey DeLong	SVP	Sell	5,000	$67.00	$335,000.00	29,250
8/3/2022	Adam J. Townsend	Insider	Sell	5,000	$56.43	$282,150.00	37,907
8/1/2022	Federico Grossi	Insider	Sell	2,500	$55.99	$139,975.00	107,384
7/27/2022	Mark Jeffrey DeLong	SVP	Sell	5,000	$57.00	$285,000.00	29,250
7/19/2022	Mark Jeffrey DeLong	SVP	Sell	5,000	$56.42	$282,100.00	29,250
7/15/2022	Alec Machiels	Director	Sell	1,250	$46.33	$57,912.50	263,774
7/11/2022	Adam J. Townsend	Insider	Sell	5,000	$48.42	$242,100.00	42,907
7/8/2022	Pascal Deschatelets	Insider	Sell	12,000	$47.95	$575,400.00	937,780
6/27/2022	A. Sinclair Dunlop	Director	Sell	1,341	$46.79	$62,745.39	1,341
6/23/2022	A. Sinclair Dunlop	Director	Sell	15,000	$45.00	$675,000.00	285,679
6/22/2022	David O. Watson	General Counsel	Sell	10,000	$44.51	$445,100.00	115,569
6/17/2022	Victoria L Brown	Insider	Sell	2,698	$45.00	$121,410.00	24,974
6/16/2022	Mark Jeffrey DeLong	SVP	Sell	10,000	$41.78	$417,800.00	29,250
6/15/2022	Alec Machiels	Director	Sell	1,250	$39.29	$49,112.50	263,774
6/8/2022	Pascal Deschatelets	Insider	Sell	12,000	$44.09	$529,080.00	891,775
6/1/2022	Federico Grossi	Insider	Sell	2,500	$41.78	$104,450.00	109,561
5/27/2022	Lukas Scheibler	Insider	Sell	10,000	$43.00	$430,000.00	40,358
5/16/2022	Alec Machiels	Director	Sell	1,250	$39.18	$48,975.00	263,774
5/2/2022	Federico Grossi	Insider	Sell	2,500	$43.56	$108,900.00	112,061
4/29/2022	Pascal Deschatelets	Insider	Sell	4,000	$44.43	$177,720.00	891,775
4/25/2022	David O. Watson	General Counsel	Sell	5,000	$50.00	$250,000.00	125,569
4/20/2022	Mark Jeffrey DeLong	SVP	Sell	7,000	$52.53	$367,710.00	28,481
4/14/2022	Alec Machiels	Director	Sell	1,250	$50.90	$63,625.00	263,774
4/4/2022	Lukas Scheibler	Insider	Sell	3,504	$56.96	$199,587.84	52,233
4/1/2022	Lukas Scheibler	Insider	Sell	11,496	$55.05	$632,854.80	52,233
3/15/2022	Alec Machiels	Director	Sell	1,250	$39.57	$49,462.50
3/15/2022	Federico Grossi	Insider	Sell	375	$39.57	$14,838.75
2/15/2022	Alec Machiels	Director	Sell	1,250	$45.43	$56,787.50
2/15/2022	Federico Grossi	Insider	Sell	375	$45.43	$17,036.25
2/11/2022	Lukas Scheibler	Insider	Sell	1,666	$46.80	$77,968.80
2/8/2022	Lukas Scheibler	Insider	Sell	10,000	$45.00	$450,000.00
1/31/2022	Lukas Scheibler	Insider	Sell	1,233	$38.47	$47,433.51
1/14/2022	Alec Machiels	Director	Sell	1,250	$40.56	$50,700.00
1/14/2022	Federico Grossi	Insider	Sell	375	$40.56	$15,210.00
12/27/2021	David O. Watson	General Counsel	Sell	1,200	$48.50	$58,200.00
12/22/2021	David O. Watson	General Counsel	Sell	10,571	$47.81	$505,399.51
11/18/2021	Morningside Venture Investment	Major Shareholder	Buy	250,000	$40.00	$10,000,000.00
11/1/2021	Federico Grossi	Insider	Sell	625	$30.70	$19,187.50
10/14/2021	Federico Grossi	Insider	Sell	750	$34.57	$25,927.50
7/21/2021	Mark Jeffrey DeLong	SVP	Sell	1,000	$65.00	$65,000.00	10,490
7/15/2021	Alec Machiels	Director	Sell	2,500	$62.30	$155,750.00	672,044
7/15/2021	Mark Jeffrey DeLong	SVP	Sell	1,000	$62.30	$62,300.00	10,490
7/14/2021	Federico Grossi	Insider	Sell	500	$64.68	$32,340.00
7/8/2021	Federico Grossi	Insider	Sell	250	$65.68	$16,420.00	63,680
6/24/2021	Pascal Deschatelets	Insider	Sell	6,250	$65.61	$410,062.50	875,837
6/15/2021	Alec Machiels	Director	Sell	2,500	$64.83	$162,075.00	672,044
6/15/2021	Mark Jeffrey DeLong	SVP	Sell	4,000	$64.96	$259,840.00	13,490
6/14/2021	Federico Grossi	Insider	Sell	500	$61.84	$30,920.00	54,930
6/11/2021	Nicole D Perry	VP	Sell	1,000	$61.55	$61,550.00	5,847
6/10/2021	Lukas Scheibler	Insider	Sell	3,417	$60.00	$205,020.00
6/1/2021	Nicole D Perry	VP	Sell	1,000	$56.40	$56,400.00	5,847
5/20/2021	A. Sinclair Dunlop	Director	Sell	5,773	$48.10	$277,681.30
5/18/2021	A. Sinclair Dunlop	Director	Sell	149,488	$52.85	$7,900,440.80
5/18/2021	Mark Jeffrey DeLong	SVP	Sell	2,000	$55.00	$110,000.00
4/30/2021	Nicole D Perry	VP	Sell	1,000	$50.00	$50,000.00	5,847
4/23/2021	Pascal Deschatelets	Insider	Sell	6,250	$46.13	$288,312.50	871,337
4/21/2021	Alec Machiels	Director	Sell	2,500	$45.76	$114,400.00	672,044

Tiny Biotech Stock Wins $75 Billion Patent

From Behind the Markets | Ad

Find out more here >>>

SEC Filings (Institutional Ownership Changes) for Apellis Pharmaceuticals (NASDAQ:APLS)

96.29% of Apellis Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Apellis Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/19/2024	Handelsinvest Investeringsforvaltning	2,697	$0.16M	0.1%	-34.2%	0.002%
4/18/2024	Allspring Global Investments Holdings LLC	115,453	$6.79M	0.0%	+94.8%	0.096%
4/17/2024	Hennion & Walsh Asset Management Inc.	14,068	$0.83M	0.0%	+14.4%	0.012%
4/15/2024	Future Financial Wealth Managment LLC	500	$29K	0.0%	N/A	0.000%
3/11/2024	Vanguard Group Inc.	9,555,678	$572M	0.0%	+0.9%	7.925%
3/1/2024	Goldman Sachs Group Inc.	310,583	$18.59M	0.0%	-11.7%	0.258%
2/22/2024	Sierra Summit Advisors LLC	3,714	$0.22M	0.1%	N/A	0.003%
2/20/2024	Eventide Asset Management LLC	209,794	$12.56M	0.2%	N/A	0.177%
2/17/2024	FIL Ltd	5,677	$0.34M	0.0%	N/A	0.005%
2/16/2024	Price T Rowe Associates Inc. MD	2,460,339	$147.28M	0.0%	+38.0%	2.076%
2/16/2024	Public Employees Retirement System of Ohio	42,322	$2.53M	0.0%	+4.2%	0.036%
2/15/2024	Exome Asset Management LLC	7,249	$0.43M	0.4%	N/A	0.006%
2/15/2024	Virtus ETF Advisers LLC	6,251	$0.37M	0.2%	+89.4%	0.005%
2/15/2024	Legal & General Group Plc	83,471	$5M	0.0%	+2.1%	0.070%
2/15/2024	Barclays PLC	196,391	$11.76M	0.0%	-67.2%	0.166%
2/15/2024	Vanguard Group Inc.	9,555,678	$572M	0.0%	+0.9%	8.064%
2/15/2024	Voya Investment Management LLC	256,533	$15.36M	0.0%	+212.2%	0.216%
2/15/2024	Nuveen Asset Management LLC	270,520	$16.19M	0.0%	-1.1%	0.228%
2/15/2024	Octagon Capital Advisors LP	2,806,980	$168.03M	26.9%	-1.7%	2.369%
2/15/2024	Prelude Capital Management LLC	8,240	$0.49M	0.0%	N/A	0.007%
2/15/2024	Price T Rowe Associates Inc. MD	2,460,339	$147.28M	0.0%	+38.0%	2.076%
2/15/2024	Profund Advisors LLC	22,558	$1.35M	0.1%	-35.8%	0.019%
2/15/2024	Frazier Life Sciences Management L.P.	885,165	$52.99M	2.8%	+44.2%	0.747%
2/15/2024	Gotham Asset Management LLC	3,513	$0.21M	0.0%	N/A	0.003%
2/15/2024	Granahan Investment Management LLC	42,241	$2.53M	0.1%	-44.5%	0.036%
2/15/2024	Baird Financial Group Inc.	25,917	$1.55M	0.0%	-37.2%	0.022%
2/15/2024	Bayesian Capital Management LP	17,275	$1.03M	0.1%	N/A	0.015%
2/15/2024	Brevan Howard Capital Management LP	4,343	$0.26M	0.0%	N/A	0.004%
2/15/2024	Comerica Bank	1,359	$81K	0.0%	-98.6%	0.001%
2/14/2024	Royal Bank of Canada	117,610	$7.04M	0.0%	-0.9%	0.099%
2/14/2024	Pathstone Holdings LLC	4,906	$0.29M	0.0%	N/A	0.004%
2/14/2024	Altitude Crest Partners Inc.	152,200	$9.11M	6.1%	N/A	0.128%
2/14/2024	Creative Planning	4,460	$0.27M	0.0%	N/A	0.004%
2/14/2024	Bellevue Group AG	821,800	$49.19M	0.8%	+3.5%	0.694%
2/14/2024	Woodward Diversified Capital LLC	3,500	$0.21M	0.1%	N/A	0.003%
2/14/2024	KPP Advisory Services LLC	11,196	$0.67M	0.6%	+17.6%	0.009%
2/14/2024	Sei Investments Co.	25,333	$1.52M	0.0%	-22.5%	0.021%
2/14/2024	Schroder Investment Management Group	23,682	$1.42M	0.0%	N/A	0.020%
2/13/2024	Envestnet Asset Management Inc.	86,428	$5.17M	0.0%	+7.4%	0.073%
2/13/2024	Northern Trust Corp	448,726	$26.86M	0.0%	-0.4%	0.379%
2/13/2024	Public Employees Retirement Association of Colorado	9,749	$0.58M	0.0%	-68.4%	0.008%
2/13/2024	Oppenheimer & Co. Inc.	12,230	$0.73M	0.0%	+3.3%	0.010%
2/13/2024	Tower Research Capital LLC TRC	4,108	$0.25M	0.0%	+320.9%	0.003%
2/13/2024	First Trust Advisors LP	93,968	$5.63M	0.0%	-76.4%	0.079%
2/13/2024	Goldman Sachs Group Inc.	310,583	$18.59M	0.0%	-11.7%	0.262%
2/13/2024	Rafferty Asset Management LLC	143,118	$8.57M	0.0%	-33.2%	0.121%
2/13/2024	Rhenman & Partners Asset Management AB	100,400	$6.01M	0.6%	-53.3%	0.085%
2/13/2024	CWA Asset Management Group LLC	3,425	$0.21M	0.0%	N/A	0.003%
2/13/2024	The Manufacturers Life Insurance Company	106,002	$6.35M	0.0%	+95.3%	0.089%
2/13/2024	KBC Group NV	1,622	$97K	0.0%	N/A	0.001%
2/13/2024	California State Teachers Retirement System	90,191	$5.40M	0.0%	-4.3%	0.076%
2/12/2024	Eagle Asset Management Inc.	446,000	$26.70M	0.1%	-0.9%	0.376%
2/12/2024	Bank of Nova Scotia	6,443	$0.39M	0.0%	-97.8%	0.005%
2/12/2024	Axiom Investors LLC DE	30,881	$1.85M	0.0%	+339.2%	0.026%
2/12/2024	Treasurer of the State of North Carolina	44,820	$2.68M	0.0%	+2.3%	0.038%
2/12/2024	Fiduciary Trust Co	242,607	$14.52M	0.2%	-8.5%	0.205%
2/12/2024	Weiss Asset Management LP	10,677	$0.64M	0.0%	N/A	0.009%
2/12/2024	Stifel Financial Corp	19,916	$1.19M	0.0%	-33.7%	0.017%
2/12/2024	TD Asset Management Inc	483,322	$28.93M	0.0%	+30.3%	0.408%
2/12/2024	Steward Partners Investment Advisory LLC	29,800	$1.78M	0.0%	+21.4%	0.025%
2/9/2024	Intech Investment Management LLC	15,342	$0.92M	0.0%	-28.0%	0.013%
2/9/2024	Orion Portfolio Solutions LLC	19,749	$1.18M	0.0%	-27.9%	0.017%
2/9/2024	Franklin Resources Inc.	229,790	$13.76M	0.0%	N/A	0.194%
2/9/2024	Assetmark Inc.	17,344	$1.04M	0.0%	+52.6%	0.015%
2/9/2024	Wells Fargo & Company MN	132,567	$7.94M	0.0%	-14.9%	0.112%
2/9/2024	UBS Group AG	95,034	$5.69M	0.0%	+2,358.2%	0.080%
2/9/2024	Norges Bank	946,213	$56.64M	0.0%	N/A	0.798%
2/8/2024	Level Four Advisory Services LLC	10,466	$0.63M	0.0%	N/A	0.009%
2/8/2024	Great Lakes Advisors LLC	208,163	$12.46M	0.1%	N/A	0.176%
2/8/2024	Fiera Capital Corp	919,090	$55.02M	0.2%	-0.1%	0.776%
2/8/2024	Vanguard Personalized Indexing Management LLC	4,695	$0.28M	0.0%	N/A	0.004%
2/7/2024	Principal Financial Group Inc.	23,863	$1.43M	0.0%	-11.6%	0.020%
2/7/2024	Dimensional Fund Advisors LP	35,567	$2.13M	0.0%	+36.4%	0.030%
2/7/2024	AGF Management Ltd.	58,496	$3.50M	0.0%	-17.3%	0.049%
2/7/2024	BNP Paribas Financial Markets	167,488	$10.03M	0.0%	-29.1%	0.141%
2/7/2024	Teacher Retirement System of Texas	19,031	$1.14M	0.0%	-17.6%	0.016%
2/7/2024	E Fund Management Co. Ltd.	7,657	$0.46M	0.0%	-30.4%	0.006%
2/6/2024	Charles Schwab Investment Management Inc.	904,409	$54.14M	0.0%	+2.8%	0.763%
2/6/2024	Lisanti Capital Growth LLC	46,305	$2.77M	0.7%	-58.3%	0.039%
2/6/2024	M&T Bank Corp	4,680	$0.28M	0.0%	N/A	0.004%
2/6/2024	Amalgamated Bank	20,457	$1.23M	0.0%	-7.8%	0.017%
2/6/2024	Swiss National Bank	162,400	$9.72M	0.0%	-9.4%	0.137%
2/5/2024	Victory Capital Management Inc.	616,272	$36.89M	0.0%	-16.6%	0.520%
2/2/2024	State of New Jersey Common Pension Fund D	53,064	$3.18M	0.0%	-13.7%	0.045%
2/1/2024	New York State Common Retirement Fund	340,507	$20.38M	0.0%	-15.5%	0.287%
2/1/2024	California Public Employees Retirement System	145,833	$8.73M	0.0%	-20.7%	0.123%
2/1/2024	Jennison Associates LLC	3,275,922	$196.10M	0.1%	-7.5%	2.764%
2/1/2024	Handelsbanken Fonder AB	22,600	$1.35M	0.0%	+31.4%	0.019%
1/31/2024	abrdn plc	169,051	$10.12M	0.0%	N/A	0.143%
1/31/2024	Knights of Columbus Asset Advisors LLC	6,193	$0.37M	0.0%	-6.5%	0.005%
1/31/2024	Xponance Inc.	12,927	$0.77M	0.0%	-6.8%	0.011%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	20,123	$1.21M	0.0%	+43.5%	0.017%
1/30/2024	Sippican Capital Advisors	16,004	$0.96M	0.8%	+1.1%	0.014%
1/30/2024	Mackenzie Financial Corp	41,485	$2.48M	0.0%	N/A	0.035%
1/26/2024	Mutual of America Capital Management LLC	30,982	$1.86M	0.0%	-25.4%	0.026%
1/25/2024	Allspring Global Investments Holdings LLC	59,275	$3.55M	0.0%	-21.5%	0.050%
1/25/2024	HC Advisors LLC	3,507	$0.21M	0.1%	N/A	0.003%
1/25/2024	Nisa Investment Advisors LLC	67,350	$4.03M	0.0%	-1.5%	0.057%
1/24/2024	Prime Capital Investment Advisors LLC	3,818	$0.23M	0.0%	N/A	0.003%
1/24/2024	Arizona State Retirement System	23,040	$1.38M	0.0%	-0.7%	0.019%

Data available starting January 2016

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $47.53

$46.53

$48.19

50 Day Range

MA: $59.71

$47.51

$71.73

52 Week Range

Now: $47.53

$19.83

$94.75

Volume

1,175,455 shs

Average Volume

1,500,053 shs

Market Capitalization

$5.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Who are the company insiders with the largest holdings of Apellis Pharmaceuticals?: Apellis Pharmaceuticals' top insider investors include:
Cedric Francois (CEO)
Pascal Deschatelets (Insider)
Alec Machiels (Director)
A Sinclair Dunlop (Director)
David O Watson (General Counsel)
Federico Grossi (Insider)
Timothy Eugene Sullivan (CFO)
Adam J Townsend (Insider)
Jeffrey Eisele (Insider)
Lukas Scheibler (Insider)
Nur Nicholson (Insider)
Mark Jeffrey Delong (Insider)
Karen Lewis (Insider)
James George Chopas (CAO)
Caroline Baumal (Insider)
Mark Jeffrey Delong (SVP)
Victoria L Brown (Insider)
Learn More about top insider investors at Apellis Pharmaceuticals.
Who are the major institutional investors of Apellis Pharmaceuticals?: Apellis Pharmaceuticals' top institutional shareholders include:
Allspring Global Investments Holdings LLC — 0.10%
Hennion & Walsh Asset Management Inc. — 0.01%
Handelsinvest Investeringsforvaltning — 0.00%
Future Financial Wealth Managment LLC — 0.00%
Portman Square Capital LLP — 0.00%
Learn More about top institutional investors of Apellis Pharmaceuticals stock.
Which institutional investors are selling Apellis Pharmaceuticals stock?: Within the last quarter, APLS stock was sold by these institutional investors:
Portman Square Capital LLP
Handelsinvest Investeringsforvaltning
In the last year, company insiders that have sold Apellis Pharmaceuticals company stock include:
Cedric Francois (CEO)
Pascal Deschatelets (Insider)
Alec Machiels (Director)
A Sinclair Dunlop (Director)
David O Watson (General Counsel)
Federico Grossi (Insider)
Timothy Eugene Sullivan (CFO)
Adam J Townsend (Insider)
Jeffrey Eisele (Insider)
Lukas Scheibler (Insider)
Nur Nicholson (Insider)
Mark Jeffrey Delong (Insider)
Karen Lewis (Insider)
James George Chopas (CAO)
Learn More investors selling Apellis Pharmaceuticals stock.
Which institutional investors are buying Apellis Pharmaceuticals stock?: During the previous quarter, APLS stock was purchased by institutional investors including:
Allspring Global Investments Holdings LLC
Hennion & Walsh Asset Management Inc.
Future Financial Wealth Managment LLC